IFU Translation: Requirements and Best Practices

When a medical device crosses a border, its Instructions for Use (IFU) must cross that border too, accurately, completely, and in full compliance with local regulations. A mistranslated dosage instruction or ambiguous safety warning can put patients at risk, trigger regulatory rejection, and result in costly product recalls. For medical device companies expanding internationally, high-quality IFU translation is not optional: it is a legal and ethical imperative.This article explains what IFU translation requires, which global standards apply, and what best practices separate compliant translations from costly mistakes. It also explains how SimulTrans, a certified medical translation company serving global life science enterprises since 1984,helps manufacturers meet these requirements in 100+ languages.

What Is an IFU and Why Does Translation Matter?

An IFU (Instructions for Use) is the official document that accompanies a medical device, drug, or in-vitro diagnostic product. It tells clinicians and patients how to safely use, maintain, clean, store, and dispose of the product. Regulators in every major market mandate that IFUs be written in the official language(s) of the country where the device is sold.

The stakes are high. In the European Union, the Medical Device Regulation (EU MDR 2017/745) requires IFUs in the official language of each Member State where a device is placed on the market. The FDA maintains similarly rigorous standards in the United States. Emerging markets, including China, India, Brazil, and South Korea, are rapidly implementing new frameworks that require comprehensive translated documentation as a condition of market entry.

For more medical translation service-related FAQs, please click here.

Key Regulatory Requirements for IFU Translation

Understanding the regulatory landscape is the first step to a compliant IFU translation program. The most relevant standards and frameworks include:

• EU MDR / IVDR: The EU Medical Device Regulation and In Vitro Diagnostic Regulation require IFUs in the language(s) of every EU Member State where the device is distributed. Translations must be accurate and complete.

• FDA (USA): The FDA requires that labeling, including IFUs, be in English. For devices marketed to non-English-speaking populations, the FDA strongly recommends translated versions to ensure patient safety and informed consent.

• ISO 17100: The international standard for translation services defines quality requirements for the translation process, including translator qualifications, revision steps, and project management. SimulTrans is ISO 17100 certified.

• ISO 9001: ISO 9001 governs the overall quality management system, while ISO 18587 addresses the post-editing of machine-translated content, relevant when AI-assisted translation is part of the workflow.

EU AI Act (Article 50): Effective in 2026, the EU AI Act requires AI-generated translations used in regulated contexts (such as medical IFUs) to include machine-readable markers or to undergo human post-editing before publication. Raw machine translation alone is no longer compliant for high-risk medical content in the EU.

IFU Translation Best Practices

• Use medical subject-matter experts: IFUs contain highly technical terminology. Translators must be native speakers of the target language and hold at least five years of specialized experience in the relevant medical field. Many should hold degrees in medicine, clinical research, or biomedical engineering. Generic linguists are not sufficient for regulatory medical documents.

• Implement a defined translation and review workflow: A compliant IFU translation follows a clear process: translation by a qualified linguist, independent linguistic review by a second expert, and a terminology accuracy check against approved glossaries. SimulTrans uses this ISO 17100-certified process on every medical project.

• Leverage translation memory: Translation memory (TM) stores previously approved translations at the segment level. When an IFU is updated, which happens frequently after design changes or regulatory revisions,  TM ensures consistent terminology and prevents re-translating identical or near-identical content, saving time and cost.

• Request back-translation for critical content: Back-translation, translating the target-language text back into the source language, provides an independent check that the meaning has been preserved. Regulatory bodies such as the FDA may require back-translation for patient-facing clinical documents and patient information leaflets.

• Obtain a certificate of translation: Many pharmaceutical, medical device, and CRO clients must demonstrate that translations are accurate and complete. A signed certificate of translation verifies this formally. SimulTrans provides electronic certificates on request.

• Ensure desktop publishing (DTP) compliance: An IFU is a formatted document, diagrams, safety symbols (per ISO 15223-1), tables, and multilingual labeling layouts must all be reproduced accurately in the translated version. Publishers with medical device experience ensure that the translated IFU renders correctly and meets regulatory formatting requirements.

• Automate ongoing updates: Medical devices are living products. IFUs are updated after post-market surveillance findings, design changes, or revised regulatory guidelines. Connecting your content management system to your translation provider via API or file-repository connectors automates file transfer and ensures IFU updates reach patients faster.

Common IFU Translation Mistakes to Avoid 

• Relying on unreviewed machine translation for regulated content
• Using general-purpose translators without medical subject-matter expertise
• Failing to update translated IFUs when the source document changes
• Omitting required safety symbols or translating symbol labels incorrectly
• Not obtaining certificates of translation when required by the regulatory authority
• Ignoring country-specific formatting requirements (e.g., paper size, font size minimums, bilingual labeling rules)

How SimulTrans Supports IFU Translation

SimulTrans is a medical translation company that has served leading life science enterprises since 1984. With ISO 9001, ISO 17100, and ISO 18587 certifications, SimulTrans provides the structured quality processes that medical device manufacturers need to maintain regulatory compliance across global markets.

SimulTrans' IFU translation services include:

• Translation and independent linguistic review by medical subject-matter experts with 5+ years of specialized experience

• ISO 17100-certified translation process covering project management, translation, and revision

• Back-translation and certificates of translation upon request

• Desktop publishing (DTP) to reproduce your IFU layout accurately in every target language

• Translation memory management to reduce costs on IFU updates and revisions

• Engineering and software localization for diagnostic software and SaMD accompanying documentation

• Human post-editing of machine-translated content in compliance with the EU AI Act

• The SimulTracker portal for project visibility and team collaboration

• System integrations to automate ongoing IFU translation workflows

SimulTrans achieved a 97% customer satisfaction rate in 2025. Experienced project managers are available to discuss your IFU translation needs and recommend the most cost-effective, compliant solution for your target markets.

Get Started with IFU Translation

If your medical device company is preparing to enter new markets with a Software as a Medical Device (SaMD), or a Software in a Medical Device (SiMD),  SimulTrans is ready to help. With 40 years of experience supplying medical translation services, ISO-certified quality processes, and a global network of medical subject-matter expert linguists, SimulTrans is the trusted IFU translation partner for life science companies worldwide.